Personalized Medicine in Ovarian Cancer: A Perspective From Mexico

被引：6

作者：

Fernandez-Garza, Luis E. ^{[1
]}

Dominguez-Vigil, Irma G. ^{[2
]}

Garza-Martinez, Jose ^{[3
]}

Valdez-Aparicio, Erick A. ^{[1
]}

Barrera-Barrera, Silvia A. ^{[4
]}

Barrera-Saldana, Hugo A. ^{[1
,5
]}

机构：

[1] Innbiogem SC Vitagenesis SA, Natl Lab Serv Res Dev & Innovat Pharma & Biotech, CONACyT Vitaxentrtun Grp, Monterrey, Nuevo Leon, Mexico

[2] Nuvance Hlth, Lab Translat Res, Rudy L Ruggles Biomed Res Inst, Danbury, CT USA

[3] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico

[4] Natl Inst Pediat, Mexico City, DF, Mexico

[5] Natl Polytech Inst, Ctr Genom Biotechnol, Reynosa, Tamaulipas, Mexico

来源：

WORLD JOURNAL OF ONCOLOGY | 2021年 / 12卷 / 04期

关键词：

Personalized medicine; Ovarian cancer; Targeted therapies; Mexico; NEOADJUVANT CHEMOTHERAPY; EPITHELIAL OVARIAN; MUTATIONS; BRCA1;

D O I：

10.14740/wjon1383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer (OC) represents a serious health problem worldwide. In Mexico, most OC patients are detected at late stages, consequently making OC one of the leading causes of death in women after reaching puberty. Personalized medicine (PM) provides an individualized therapeutic opportunity for treating each patient relying on "omic" tools to match the correct drug with the specific pathogenic genomic signature. PM can help predict the best therapeutic option for each affected woman suffering from OC. In recent years, Mexico has made contributions to the PM of OC; however, it still has a long way to go for its full implementation in the country's health system.

引用

页码：85 / 92

页数：8

共 42 条

[1] A novel method to detect the Mexican founder mutation BRCA1 ex9-12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes [J].

Aidee Martinez-Trevino, Denisse ;

eyes Leon-Cachon, Rafael Baltazar ;

Villarreal-Garza, Cynthia ;

Aguilar Y Mendez, Dione ;

Aguilar-Martinez, Elisa ;

Alberto Barrera-Saldana, Hugo .

MOLECULAR MEDICINE REPORTS, 2018, 18 (02) :1531-1537

[2]

American Cancer Society, 2020, KEY STAT OV CANC

[3]

American Cancer Society, 2020, WHAT IS OV CANC WHAT IS OV CANC

[4]

[Anonymous], 2016, OBSTET GYNECOL SURV, V71, P223

[5]

[Anonymous], 2020, CLIN TRIALS SEARCH O

[6]

[Anonymous], 2015, PRACT BAS COMP GEN C PRACT BAS COMP GEN C, P1

[7] miRNA Processing and Human Cancer: DICER1 Cuts the Mustard [J].

Bahubeshi, Amin ;

Tischkowitz, Marc ;

Foulkes, William D. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (111)

[8] Origin of personalized medicine in pioneering, passionate, genomic research [J].

Barrera-Saldana, Hugo A. .

GENOMICS, 2020, 112 (01) :721-728

[9] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[10] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].

Bitler, Benjamin G. ;

Aird, Katherine M. ;

Garipov, Azat ;

Li, Hua ;

Amatangelo, Michael ;

Kossenkov, Andrew V. ;

Schultz, David C. ;

Liu, Qin ;

Shih, Ie-Ming ;

Conejo-Garcia, Jose R. ;

Speicher, David W. ;

Zhang, Rugang .

NATURE MEDICINE, 2015, 21 (03) :231-+

← 1 2 3 4 5 →